Moderna (MRNA) Stock Looks Stretched On Sales But Reasonable On Momentum
Moderna stock has surged 118.5% year to date, yet the company screens as expensive on Simply Wall St's broader valuation checks. This raises a clear question about how much optimism is already built into the current price.
- The 118.5% gain so far this year suggests investors are pricing in a lot of confidence around Moderna's pipeline and future vaccine revenues.
- Expectations around upcoming regulatory decisions on its vaccines can support that optimism, but the stock's history of deeper drawdowns during market stress highlights how sensitive the valuation may be to any setback in those programs.
- With a value score of 0 out of 6, Moderna does not currently screen as a clear bargain on the broader set of valuation checks.
The issue now is whether Moderna's recent rally leaves enough margin of safety for investors at today's valuation.
Is Moderna Getting Expensive on Sales?
The P/S ratio is a useful yardstick for Moderna because earnings are currently negative, so sales give a clearer anchor for valuation. Moderna trades on a P/S of 12.0x, slightly above the broader biotech industry average of 11.2x and more than double the peer group average of 5.3x.
The model based on Moderna's growth profile, margins, scale and risk suggests a fair P/S ratio of about 2.7x. That is far below the current 12.0x. Because the gap is so wide, it is better read as a signal that this framework is heavily penalising the company's ongoing losses and the uncertainty around future vaccine and pipeline revenues, rather than as a precise target. Despite the recent excitement around upcoming vaccine decisions and large contracts, the current multiple still indicates that investors are paying a high premium for Moderna's sales compared with typical biotech peers.
On the P/S multiple, Moderna stock currently appears significantly overvalued, with the market paying a substantial premium to both peers and the model's fair range.
See what the numbers say about this price — find out in our valuation breakdown.
The Moderna Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where Moderna's valuation puzzle leaves off by spelling out the specific combinations of growth, margins and earnings that would need to play out for the stock to be worth materially more or less than today's price on the Community page. Each one links its number to a clear view on how Moderna's revenue potential, profitability and risks might evolve, giving you a reference point to revisit as new information emerges.
One of the top community narratives on Moderna: 52% overvalued
"Despite analysts expecting the underlying business to improve, they seem to believe the market's expectations are too high..."
Read one of the top narratives on Moderna
Do you think there's more to the story for Moderna? Head over to our Community to see what others are saying!
The Bottom Line
For Moderna, the market-multiple view points to the stock as overvalued, with investors placing a rich price on current sales relative to peers. That gap is unusually wide and reflects how much weight the market is putting on future vaccine and pipeline outcomes while the valuation model heavily discounts ongoing losses and execution risk. From here, the key question is whether Moderna can deliver the revenue scale and profitability that keep this premium P/S multiple intact, or whether expectations reset closer to typical biotech levels.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com